Ratings by Cantor Fitzgerald (Jennifer Kim)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/26/2025 | Precigen Inc. | PGEN | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/19/2025 | Precigen Inc. | PGEN | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/15/2025 | Belite Bio, Inc, ADR | BLTE | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/15/2025 | Precigen Inc. | PGEN | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/11/2025 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/20/2025 | Precigen Inc. | PGEN | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/5/2025 | EyePoint Pharmaceuticals, Inc. | EYPT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/26/2024 | Poseida Therapeutics, Inc | PSTX | Downgrade | Neutral (Overweight) |
2.86 (9.50) |
232.17% | Details | |
| 1/16/2024 | Allakos Inc. | ALLK | Downgrade | Neutral (Buy) |
2.99 (0.33) |
-88.96% | Details | |
| 1/8/2024 | Harpoon Therapeutics | HARP | Downgrade | Hold (Buy) |
10.55 (23.01) |
118.1% | Details | |
| 8/15/2023 | Checkpoint Therapeutics | CKPT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2023 | Poseida Therapeutics, Inc | PSTX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/28/2023 | Belite Bio, Inc, ADR | BLTE | New Coverage | Overweight (N/A) |
20.55 (120.56) |
486.67% | Details | |
| 5/17/2023 | ProQR Therapeutics N.V. | PRQR | Maintain | Overweight (N/A) |
|
Details | ||
| 5/16/2023 | Fortress Biotech | FBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/13/2023 | Poseida Therapeutics, Inc | PSTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2023 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 2/22/2023 | Aytu Biosciences | AYTU | Maintain | Overweight (N/A) |
|
Details | ||
| 1/30/2023 | Precigen Inc. | PGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/22/2022 | ProQR Therapeutics N.V. | PRQR | Upgrade | Overweight (Neutral) |
1.65 (1.78) |
7.88% | Details | |
| 11/18/2022 | Precigen Inc. | PGEN | New Coverage | Overweight (N/A) |
1.85 (3.32) |
79.46% | Details | |
| 10/13/2022 | EyePoint Pharmaceuticals, Inc. | EYPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/12/2022 | ProQR Therapeutics N.V. | PRQR | Downgrade | Neutral (Buy) |
0.81 (1.78) |
119.75% | Details | |
| 8/8/2022 | Lipocine Inc | LPCN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/19/2022 | EyePoint Pharmaceuticals, Inc. | EYPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/2/2022 | Ocugen, Inc. | OCGN | New Coverage | Overweight (N/A) |
2.17 (1.61) |
-25.81% | Details | |
| 5/18/2022 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/17/2022 | Aytu Biosciences | AYTU | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/13/2022 | Poseida Therapeutics, Inc | PSTX | New Coverage | Overweight (N/A) |
1.87 (9.50) |
408.02% | Details | |
| 5/13/2022 | Harpoon Therapeutics | HARP | New Coverage | Overweight (N/A) |
1.86 (23.01) |
1137.1% | Details | |
| 5/13/2022 | Fortress Biotech | FBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/13/2022 | Checkpoint Therapeutics | CKPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/12/2022 | ProQR Therapeutics N.V. | PRQR | New Coverage | Overweight (Overweight) |
0.56 (1.78) |
217.86% | Details | |
| 4/6/2022 | Fortress Biotech | FBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/29/2022 | Fortress Biotech | FBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/25/2022 | Graybug Vision | GRAY | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/23/2022 | Aytu Biosciences | AYTU | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/14/2022 | Novan | NOVN | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/10/2022 | Graybug Vision | GRAY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/9/2022 | Lipocine Inc | LPCN | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/3/2022 | EyePoint Pharmaceuticals, Inc. | EYPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/22/2022 | Novan | NOVN | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/17/2022 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/15/2022 | Aytu Biosciences | AYTU | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/3/2022 | Lipocine Inc | LPCN | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/25/2022 | Checkpoint Therapeutics | CKPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/25/2022 | Checkpoint Therapeutics | CKPT | Maintain | Overweight (N/A) |
|
Details | ||
| 1/19/2022 | EyePoint Pharmaceuticals, Inc. | EYPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/15/2021 | EyePoint Pharmaceuticals, Inc. | EYPT | Maintain | Overweight (N/A) |
|
Details | ||
| 10/8/2021 | Insmed | INSM | New Coverage | Overweight (N/A) |
27.61 (164.02) |
494.06% | Details | |
| 9/29/2021 | Fortress Biotech | FBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 9/21/2021 | Novan | NOVN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/9/2021 | Novan | NOVN | New Coverage | Overweight (N/A) |
9.10 (0.09) |
-99.01% | Details | |
| 4/13/2021 | Fortress Biotech | FBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/30/2021 | Aytu Biosciences | AYTU | New Coverage | Overweight (N/A) |
7.71 (2.52) |
-67.32% | Details | |
| 1/27/2021 | EyePoint Pharmaceuticals, Inc. | EYPT | New Coverage | Overweight (N/A) |
10.23 (15.75) |
53.96% | Details | |
| 1/20/2021 | Checkpoint Therapeutics | CKPT | New Coverage | Overweight (N/A) |
3.35 (4.26) |
27.16% | Details | |
| 12/22/2020 | Graybug Vision | GRAY | New Coverage | Overweight (N/A) |
25.51 (5.50) |
-78.44% | Details | |
| 2/13/2020 | Fortress Biotech | FBIO | New Coverage | Overweight (N/A) |
2.66 (3.34) |
25.56% | Details |
